Literature DB >> 18607784

Prolonged response to gefitinib in bone metastasis.

Hiroaki Satoh1, Hiroichi Ishikawa, Gen Ohara, Norihiro Kikuchi, Kiyohisa Sekizawa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18607784     DOI： 10.1007/s12032-008-9082-y

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


× No keyword cloud information.
  6 in total

Review 1.  Bone metastasis: review and critical analysis of random allocation trials of local field treatment.

Authors:  V Ratanatharathorn; W E Powers; W T Moss; C A Perez
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-04-01       Impact factor: 7.038

2.  Long-term survival cases of lung cancer presented as solitary bone metastasis.

Authors:  Yasumitsu Hirano; Makoto Oda; Yoshio Tsunezuka; Norihiko Ishikawa; Go Watanabe
Journal:  Ann Thorac Cardiovasc Surg       Date:  2005-12       Impact factor: 1.520

3.  Long-term survival after second-line therapy with docetaxel and carboplatin and monthly pamidronic acid in a woman with metastatic non-small cell lung cancer.

Authors:  Birte Andritzky; Gunter Schuch; Ina Thoem; Michael Goern; Stephan Brandl; Carsten Bokemeyer; Eckart Laack
Journal:  Onkologie       Date:  2006-05-03

4.  Cure in a patient with multiple osseus metastases in non-small cell lung cancer: a case report.

Authors:  H Hawighorst; G Gademann
Journal:  Strahlenther Onkol       Date:  1993-10       Impact factor: 3.621

5.  Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

Authors:  Mark G Kris; Ronald B Natale; Roy S Herbst; Thomas J Lynch; Diane Prager; Chandra P Belani; Joan H Schiller; Karen Kelly; Harris Spiridonidis; Alan Sandler; Kathy S Albain; David Cella; Michael K Wolf; Steven D Averbuch; Judith J Ochs; Andrea C Kay
Journal:  JAMA       Date:  2003-10-22       Impact factor: 56.272

6.  Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

Authors:  Masahiro Fukuoka; Seiji Yano; Giuseppe Giaccone; Tomohide Tamura; Kazuhiko Nakagawa; Jean-Yves Douillard; Yutaka Nishiwaki; Johan Vansteenkiste; Shinzoh Kudoh; Danny Rischin; Richard Eek; Takeshi Horai; Kazumasa Noda; Ichiro Takata; Egbert Smit; Steven Averbuch; Angela Macleod; Andrea Feyereislova; Rui-Ping Dong; José Baselga
Journal:  J Clin Oncol       Date:  2003-05-14       Impact factor: 44.544
  6 in total
  3 in total

1.  Osteosclerotic lesions in patients treated with gefitinib for lung adenocarcinomas: a sign of favorable therapeutic response.

Authors:  Yoshiko Yamashita; Takatoshi Aoki; Takeshi Hanagiri; Chiharu Yoshii; Hiroshi Mukae; Hidetaka Uramoto; Yukunori Korogi
Journal:  Skeletal Radiol       Date:  2011-08-25       Impact factor: 2.199

2.  Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung cancer cell line NCI-H292.

Authors:  Koh Furugaki; Yoichiro Moriya; Toshiki Iwai; Keigo Yorozu; Mieko Yanagisawa; Kumiko Kondoh; Kaori Fujimoto-Ohuchi; Kazushige Mori
Journal:  Clin Exp Metastasis       Date:  2011-06-18       Impact factor: 5.150

3.  Recovery from paraplegia with administration of erlotinib in a patient with lung adenocarcinoma.

Authors:  Koichi Kurishima; Katsunori Kagohashi; Takeo Mammoto; Hiroaki Satoh
Journal:  Contemp Oncol (Pozn)       Date:  2014-06-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.